Your immune system usually protects you from infections or disease. But when you have lupus nephritis, your immune system mistakenly attacks the healthy cells in your body.
In lupus nephritis, B cells, a type of white blood cells, create harmful antibodies that attack your kidneys. This makes it difficult for your kidneys to work properly and can lead to damage if left unchecked.
That’s where GAZYVA comes in. B cells play a big role in the disease, and GAZYVA was designed to help eliminate them.
B-cell depletion has not been shown to be directly correlated to clinical response.
*A treatment that uses 2 types of medicine, usually a steroid and an immunosuppressant like MMF (mycophenolate mofetil), to manage lupus nephritis.
Learn about GAZYVA results from the clinical trial.
A type of kidney disease caused by lupus. The immune system attacks the kidneys, causing inflammation and damage.
A medicine used to treat lupus nephritis. It is often part of standard or advanced therapy.
A treatment that uses 2 types of medicine, usually a steroid and an immunosuppressant like MMF (mycophenolate mofetil), to manage lupus nephritis.
Having low protein in the urine, maintaining kidney function, and showing no active signs of inflammation.
Medicines that reduce inflammation but can cause side effects when used in high doses for a long time
You are leaving the GAZYVA® (obinutuzumab) site and connecting to a site that is under the shared control of Genentech, Inc. and AbbVie Inc, and may be governed by its own set of terms and conditions and privacy policy.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.